Metastatic Breast Cancer

Ibrance® Approved for Use in Combination with Faslodex® in Hormone-Positive Breast Cancer (03-17-2016)

The United States Food and Drug Administration (FDA) has approved Ibrance (palbociclib) to be used with Faslodex (fulvestrant) for women with hormone-positive (HR-positive), human epidermal growth factor receptor-2 (HER2)-negative, metastatic breast cancer... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (01-25-2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer (01-6-2016)

Patients with metastatic, HER2-positive breast cancer who received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute... Continue Reading

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer (01-3-2016)

Patients with metastatic, HER2-positive breast cancer received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported... Continue Reading

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer (10-9-2015)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. According... Continue Reading

No Benefit with Addition of Onartuzumab to Taxol® with or without Avastin® in Triple-Negative Breast Cancer (09-29-2015)

The addition of the targeted therapy onartuzumab to Taxol® (paclitaxel) with or without Avastin® (bevacizumab) does not appear to help control disease or improve survival in patients with metastatic triple-negative breast cancer. These findings were... Continue Reading

Role of Tumor Size and Estrogen-Receptor Status in Decline in Breast Cancer Deaths (08-4-2015)

In light of a general decline in breast cancer death since the late 1980s, research has now turned to how type and stage of disease affect survival among different women. These findings, which considered tumor size and estrogen-receptor (ER) status,... Continue Reading

Combination of Ibrance® plus Faslodex® Promising in Advanced Hormone-Positive Breast Cancer (06-3-2015)

The combination of Ibrance® (palbociclib) and Faslodex® (fulvestrant) appears to extend progression-free survival in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER)-negative metastatic breast cancer. These... Continue Reading

Platinum-Based Chemotherapy Active in Metastatic Triple-Negative Breast Cancer (05-26-2015)

Platinum-based chemotherapy appears active in the treatment of metastatic triple-negative breast cancers, particularly among patients with a BRCA1/2 mutation. These findings were reported in the Journal of Clinical Oncology. Breast cancers that are not... Continue Reading

Herceptin Superior to Tykerb for Treatment of HER2-positive Breast Cancer (03-24-2015)

In patients with human epidermal growth factor receptor (HER2)–positive advanced breast cancer, the combination of Herceptin® (trastuzumab) plus a taxane resulted in delayed time to cancer progression and was associated with fewer side effects than... Continue Reading

« Previous PageNext Page »